CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
4.110
+0.100 (2.49%)
At close: Mar 6, 2026, 4:00 PM EST
4.100
-0.010 (-0.24%)
After-hours: Mar 6, 2026, 6:19 PM EST
CervoMed Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CervoMed stock have an average target of 21.5, with a low estimate of 15 and a high estimate of 31. The average target predicts an increase of 423.11% from the current stock price of 4.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CervoMed stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +264.96% | Mar 5, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +654.26% | Mar 4, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +654.26% | Feb 18, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +508.27% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
5.07M
from 9.74M
Decreased by -47.99%
Revenue Next Year
918.00K
from 5.07M
Decreased by -81.88%
EPS This Year
-2.74
from -2.02
EPS Next Year
-1.93
from -2.74
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7.3M | 5.0M | ||||
| Avg | 5.1M | 918,000 | ||||
| Low | 3.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -24.5% | -0.5% | ||||
| Avg | -48.0% | -81.9% | ||||
| Low | -59.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.27 | -0.57 | ||||
| Avg | -2.74 | -1.93 | ||||
| Low | -2.94 | -2.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.